The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
20120452: Lime Rock Partners V, L.P.; Archer Limited
20120427: Fossil, Inc.; Henrik Jorst
20120456: Audax Private Equity Fund III, L.P.; Morgenthaler Management Partners VII, L.P.
20120440: Post Oak Companies, LP; Prospect Capital Corporation
20120431: Alexion Pharmaceuticals, Inc.; Enobia Pharma Corp.
Laboratory Corporation of America Holdings, and Orchid Cellmark Inc.
The Commission required laboratory testing companies Laboratory Corporation of America Holdings and Orchid Cellmark Inc. to divest a portion of Orchid's paternity testing business, to resolve the FTC complaint alleging that LabCorp's $85.4 million acquisition of Orchid would have an anticompetitive impact in the market for paternity testing services used by government agencies. Under the proposed settlement order, the portion of Orchid's U.S. paternity testing business that is focused on sales to government agencies, and related assets, will be sold to another testing company, DNA Diagnostics Center (DDC). On 2/1/2012, the FTC approved a final order.